Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41200   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-002323-15
    Sponsor's Protocol Code Number:I4V-MC-JADW
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-01-09
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2012-002323-15
    A.3Full title of the trial
    A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
    Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de baricitinib (LY3009104) en pacientes con artritis reumatoide con actividad moderada-severa y respuesta insuficiente a un tratamiento con fármacos inhibidores del factor de necrosis tumoral
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis
    Estudio de fase 3 en pacientes con artritis reumatoide con actividad moderada-severa
    A.3.2Name or abbreviated title of the trial where available
    RA - BEACON
    A.4.1Sponsor's protocol code numberI4V-MC-JADW
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLilly S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportLilly S.A.
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationLilly
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street AddressAvda de la Industria 30
    B.5.3.2Town/ cityAlcobendas Madrid
    B.5.3.3Post code28108
    B.5.3.4CountrySpain
    B.5.4Telephone number34916635354
    B.5.5Fax number34916635327
    B.5.6E-mailEU_Lilly_Clinical_Trials@lilly.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebaricitinib
    D.3.2Product code LY3009104
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNN/A
    D.3.9.1CAS number N/A
    D.3.9.2Current sponsor codeLY3009104
    D.3.9.3Other descriptive namebaricitinib
    D.3.9.4EV Substance CodeN/A
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebaricitinib
    D.3.2Product code LY3009104
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNN/A
    D.3.9.1CAS number N/A
    D.3.9.2Current sponsor codeLY3009104
    D.3.9.3Other descriptive namebaricitinib
    D.3.9.4EV Substance CodeN/A
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Moderately to severely active rheumatoid arthritis
    Artritis reumatoide moderada o severa
    E.1.1.1Medical condition in easily understood language
    Rheumatoid arthritis
    Artritis Reumatoide
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10039073
    E.1.2Term Rheumatoid arthritis
    E.1.2System Organ Class 10028395 - Musculoskeletal and connective tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Determine whether baricitinib 4 mg QD is superior to placebo in the treatment of patients with moderately to severely active RA who have had an inadequate response to a TNF inhibitor, despite ongoing treatment with cDMARDs, as assessed by the proportion of patients achieving ACR20 at Week 12.
    El objetivo principal del estudio es determinar si baricitinib 4 mg QD es superior a placebo en el tratamiento de pacientes con artritis reumatoide (AR) con actividad moderada-severa, que han presentado una respuesta inadecuada a un inhibidor del TNF, a pesar de estar recibiendo un tratamiento con FARMEc. Ello se determinará de acuerdo con la proporción de pacientes que en la semana 12 presenten una mejoría del 20%, de acuerdo con los criterios del Colegio Americano de Reumatología (ACR20).
    E.2.2Secondary objectives of the trial
    - change from baseline to Week 12 in Health Assessment Questionnaire-Disability Index (HAQ-DI) score (baricitinib 4mg compared to placebo)
    - change from baseline to Week 12 in DAS28-high-sensitivity C-reactive protein (hsCRP) (baricitinib 4mg compared to placebo)
    - proportion of patients achieving ACR20 at Week 12 (baricitinib 2mg compared to placebo)
    - change from baseline to Week 12 in HAQ-DI score (baricitinib 2mg compared to placebo)
    - change from baseline to Week 12 in DAS28-hsCRP (baricitinib 2mg compared to placebo)
    Evaluar la eficacia de baricitinib 4 mg QD, en comparación con placebo, de acuerdo con
    los siguientes parámetros:
    o Cambio observado en el período comprendido entre el momento basal y la
    semana 12, en relación con la puntuación del Cuestionario de Evaluación de la
    Salud ? Índice de Discapacidad (HAD-DI).
    o Cambio observado en el período comprendido entre el momento basal y la
    semana 12, en relación con la puntuación DAS28 ? proteína C reactiva de alta
    sensibilidad (hsCRP).
    · Evaluar la eficacia de baricitinib 2 mg QD, en comparación con placebo, de acuerdo con
    los siguientes parámetros:
    o Proporción de pacientes que alcancen una ACR20 en la semana 12.
    o Cambio observado en la semana 12 respecto a la puntuación basal en el
    cuestionario HAQ-DI.
    o Cambio observado en la semana 12 respecto al valor basal de DAS28-hsCRP
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    ? are at least 18 years of age
    ? have a diagnosis of adult-onset RA as defined by the ACR/EULAR 2010 Criteria for the Classification of RA
    ? have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints
    ? have a C-reactive protein (or hsCRP) measurement ?1 times the upper limit of normal (ULN)
    ? have been treated at approved doses with at least 1 biologic TNF- ? inhibitor and either:
    - experienced insufficient efficacy or loss of efficacy
    - experienced intolerance of such treatment
    ? have had regular use of at least 1 cDMARD for at least the 12 weeks prior to study entry with a continuous, nonchanging dose for at least 8 weeks prior to study entry
    [1] Tengan al menos 18 años de edad.
    [2] Diagnóstico de artritis reumatoide en la edad adulta, de acuerdo con los
    Criterios para la Clasificación de la AR de la ACR/EULAR 2010 (Aletaha et
    al. 2010)
    [3] Presenten AR con actividad moderada-severa, definida por la presencia de al
    menos 6/68 articulaciones dolorosas con la palpación y de al menos 6/66
    articulaciones tumefactas.
    a. En caso de que se haya realizado una intervención quirúrgica en una
    articulación, dicha articulación no puede incluirse en el recuento de
    articulaciones dolorosas con la palpación ni de articulaciones
    tumefactas, a los efectos de inclusión o reclutamiento en el estudio.
    [4] Presenten una concentración de proteína C reactiva (o hsCRP) ? 1 veces el
    límite superior de la normalidad (LSN), basándose en los datos más recientes
    (en caso de disponer de estos).
    [5] Haber recibido tratamiento con dosis aprobadas de al menos 1 fármaco
    biológico inhibidor del TNF-? (por ejemplo, infliximab, certolizumab,
    golimumab, etanercept, adalimumab) al menos durante 3 meses y que, en
    opinión del investigador:
    a. La eficacia haya sido insuficiente o esta se haya perdido, a una dosis
    que, de acuerdo con la práctica clínica local, se considere aceptable
    para evaluar la respuesta clínica de forma apropiada o b. Hayan mostrado intolerancia a dicho tratamiento.
    [6] Hayan tomado al menos 1 FARMEc de forma regular, al menos durante las 12
    semanas previas a la inclusión en el estudio, a una dosis que, de acuerdo con
    la práctica clínica local, se considere aceptable para evaluar la respuesta
    clínica de forma apropiada, según se especifica a continuación:
    a. Los pacientes deberán haber estado recibiendo una dosis estable (esto es, sin ningún tipo de ajuste) de MTX (entre 7,5 y 25mg/semana) por vía oral (o la dosis inyectable equivalente), al menos durante las 8 semanas previas a la inclusión en el estudio. Se espera que la dosis de MTX se mantenga estable a lo largo del estudio, y que se ajuste únicamente por razones de seguridad.
    b. En relación con aquellos pacientes que en el momento de inclusión
    en el estudio estén recibiendo dosis de MTX < 15 mg/semana, en la historia clínica deberá documentarse claramente que el paciente no toleró dosis más altas de MTX, o que la dosis de MTX es la máxima dosis aceptable, de acuerdo con la práctica clínica local.
    c. A la hora de administrar ácido fólico de forma concomitante, deberán seguirse las normas asistenciales locales.
    d. En relación con aquellos pacientes que en el momento de inclusión en el estudio estén recibiendo los siguientes FARME, deberá haberse recibido una dosis estable de estos, al menos durante las 8 semanas previas a la inclusión en el estudio, y dicha dosis no deberá ser superior a las dosis que se muestran a continuación: hidroxicloroquina, hasta 400 mg/día; sulfasalazina, hasta 3000 mg/día; leflunomida (Arava®, Sanofi-Aventis), hasta 20 mg/día; y azatioprina, hasta 150 mg/día o 2 mg/kg/día.
    [7] Sean capaces de leer, comprender y firmar el consentimiento informado
    E.4Principal exclusion criteria
    ? have received a biologic treatment for RA within 28 days of planned randomization
    ? are currently receiving corticosteroids at doses >10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization
    ? have started treatment with NSAIDs or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization
    ? are currently receiving concomitant treatment with MTX, hydroxychloroquine, and sulfasalazine
    ? have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
    ? have had 3 or more joints injected with intraarticular corticosteroids within 2 weeks prior to study entry or within 6 weeks prior to planned randomization
    ? have active fibromyalgia that, in the investigator?s opinion, would make it difficult to appropriately assess RA activity for the purposes of this study
    ? have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to juvenile chronic arthritis, spondyloarthropathy, Crohn?s disease, ulcerative colitis, psoriatic arthritis, or active vasculitis
    - Patients with secondary Sjogren?s syndrome are not excluded.
    ? have a diagnosis of Felty?s syndrome
    ? have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the patient
    ? have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure
    ? have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data
    ? are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair
    ? have an eGFR based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of <40 mL/min/1.73 m2
    ? have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total bilirubin ?1.5 times the ULN
    ? have, or have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years
    ? have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)
    ? have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection
    ? have had symptomatic herpes zoster infection within 12 weeks prior to study entry
    ? have a history of disseminated/complicated herpes zoster (eg, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, postherpetic neuralgia)
    ? are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study
    ? have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
    ? have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population or investigative site that, in the opinion of the investigator, pose an unacceptable risk for the patient?s participation in the study
    ? have screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the patient?s participation in the study (eg, Fridericia?s corrected QT interval >500 msec for men and >520 msec for women)
    ? have symptomatic herpes simplex at the time of study enrollment
    ? have evidence of active or latent TB
    [8] REcibir un tratamiento biológico para la AR (etanercept,anakinra, infliximab, tocilizumab, certolizumab, adalimumab, golimumab oabatacept),durante los 28 días previos a aleatorización; rituximab durante 6 meses previos a aleatorización.
    [9] Recibir corticoest a ds > 10 mg de prednisona/día o hayan estado recibiendo una ds inestable de corticoest en el transcurso de las 2 sem previas a la inclusión en el estudio, o en el transcurso de las 6 sem previas a la fecha prevista de aleatorización.
    [10] Recibir AINE en el transcurso de las 2 sem previas a la inclusión del estudio o en el transcurso de las 6 sem previas a la fecha prevista de aleatorización, o hayan estado recibiendo una ds inestable de un AINE en el transcurso de las 2 sem previas a la inclusión del estudio o en el transcurso de las 6 sem previas a la fecha prevista de aleatorización.
    [11] Recibir actualmente un tratamiento concomitante con MTX, hidroxicloroquina y sulfasalazina.
    [12] Comenzar un nuevo tratamiento fisioterápico para la AR, en el transcurso de las 2 sem previas a la inclusión en el estudio.
    [13] Recibir corticoest, administrados por vía parenteral, en el transcurso de las 2 sem previas a la inclusión en el estudio, o en el transcurso de las 6 sem previas a la fecha prevista de aleatorización, o se prevea que vayan a requerir inyecciones parenterales de corticoest durante el estudio.
    [14] Recibir corticoest por vía intraarticular en ? 3 articulaciones, en el transcurso de las 2 sem previas a la inclusión en el estudio, o en el transcurso de las 6 sem previas a la fecha prevista de aleatorización.
    [15] Presenten fibromialgia activa que pueda dificultar que se evalúe la actividad de la AR
    [16] Tener cualquier enfermedad inflamatoria sistémica (distinta a la AR)
    a. No se excluirá a los pacientes con síndrome de Sjögren secundario.
    [17] Se les haya diagnosticado el síndrome de Felty.
    [18] Se hayan sometido a una intervención de cirugía mayor en el transcurso de las 8 sem previas a la inclusión, o requieran someterse a una intervención
    [19] Hayan experimentado en el transcurso de las 12 sem previas a la inclusión en el estudio infarto de miocardio, cardiopatía isquémica inestable, ictus o insuficiencia cardiaca
    [20] Tengan antecedentes o presenten trastornos cardiovasculares, respiratorios, hepáticos, gastrointestinales, endocrinos, hematológicos, neurológicos o neuropsiquiátricos, o cualquier otra enfermedad grave y/o inestable
    [21] Tener discapacidad significativa o total.
    [22] TFGe < 40 ml/min/1,73 m2.
    [23] Antecedentes de enfermedad hepática crónica.
    [24] Presenten o tengan antecedentes de enfermedad linfoproliferativa, o signos o síntomas que sugieran la posibilidad de enfermedad linfoproliferativa significativa que haya estado en remisión < 5 años.
    a. Los pacientes con cáncer de cuello uterino in situ que haya sido reseccionado y no hayan presentado indicios de recurrencia o de enfermedad metastásica al menos durante 3 años podrán participar.
    b. Los pacientes con carcinoma de células basales o carcinoma escamoso de la piel que haya sido reseccionado completamente y no hayan presentado indicios de recurrencia al menos durante 3 años podrán participar.
    [25] Recibir vacuna viva en el transcurso de las 12 sem previas
    [27] Experimentar una infección sintomática por herpes zóster
    [28] Antecedentes de herpes zóster diseminado/con complicaciones.
    [29] Estén inmunodeprimidos..
    [30] Antecedentes de virus de la hepatitis B, hepatitis C o virus de VIH
    [31] Algún miembro de su familia con el que tenga contacto haya presentado infección activa por TB y el potencial participante no haya recibido un tratamiento profiláctico (documentado) para la TB.
    [32] Presentar indicios de infección activa por TB, o antecedentes de infección activa por TB, y no hayan recibido un tratamiento adecuado para la TB.
    [33] Embarazadas o en período de lactancia.
    [34] Mujeres en edad fértil que no consientan en utilizar 2 métodos anticonceptivos
    [35] Varones que no consientan en utilizar 2 métodos anticonceptivos.
    [36] Hayan donado > 500 ml de sangre, en el transcurso de los 30 días previos
    [37] Antecedentes de alcoholismo crónico, drogadicción u otra toxicomanía ilegal, en el transcurso de los 2 años previos.
    [38] Hayan sido aleatorizados previamente en este estudio o en cualquier otro estudio en el que se investigue baricitinib.
    [39] No puedan y/o no estén disponibles durante la duración del estudio y/o no estén dispuestos a seguir el estudio.
    [40] Recibir tratamiento previo con un inhibidor oral de las cinasas Janus.
    [41] Ser personal del centro de investigación, directamente relacionado con el estudio, y/o familiares cercanos.
    [42] Ser empleados de Lilly o Incyte o de uno de sus representantes.
    [43] Participar en la actualidad, o hayan abandonado en el transcurso de los 30 días previos a la inclusión en el estudio un ensayo en el que se administre un fármaco de investigación.
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of patients achieving ACR20 response (baricitinib 4mg compared to placebo)
    Proporción de pacientes que alcancen una
    respuesta ACR20 en la semana 12
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 12
    12 semanas
    E.5.2Secondary end point(s)
    - Health Assessment Questionnaire-Disability Index (HAQ-DI) score
    - DAS28-high-sensitivity C-reactive protein (hsCRP)
    - Proportion of patients achieving ACR20 response (baricitinib 2mg compared to placebo)
    - Proportion of patients achieving ACR20 response
    - Proportion of patients achieving ACR50 and ACR70 response
    - proportion of patients achieving DAS28-hsCRP ?3.2; proportion of patients achieving DAS28- hsCRP <2.6
    - proportion of patients achieving DAS28-ESR ?3.2; proportion of patients achieving DAS28- ESR <2.6
    - Puntuacion Cuestionario de Evaluación del Estado de Salud ? Índice de Discapacidad
    - Puntuación modificada de la actividad de la enfermedad para incluir el recuento de las 28 articulaciones diartrodiales.)
    - Tasa de pacientes que hayan conseguido una respuesta a ACR20 (baricitinib 2mg comparado con placebo)
    -- Tasa de pacientes que hayan conseguido una respuesta a ACR20
    - Tasa de pacientes que hayan conseguido una respuesta a ACR50 y ACR70
    - Proporcion de pacientes que hayan conseguido una DAS28-hsCRP ?3.2; Proporcion de pacientes que hayan conseguido unaDAS28- hsCRP <2.6
    - Proporcion de pacientes que hayan conseguido una DAS28-ESR ?3.2; Proporcion de pacientes que hayan conseguido una DAS28- ESR <2.6
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Health Assessment Questionnaire-Disability Index (HAQ-DI) score: Change from baseline to Weeks 12 and 24
    - DAS28-high-sensitivity C-reactive protein (hsCRP): Change from baseline to Weeks 12 and 24
    - Proportion of patients achieving ACR20 response (baricitinib 2mg compared to placebo): Week 12
    - Proportion of patients achieving ACR20 response: Week 24
    - Proportion of patients achieving ACR50 and ACR70 response: Weeks 12 and 24
    - proportion of patients achieving DAS28-hsCRP ?3.2; proportion of patients achieving DAS28- hsCRP <2.6: Weeks 12 and 24
    - proportion of patients achieving DAS28-ESR ?3.2; proportion of patients achieving DAS28- ESR <2.6: Weeks 12 and 24
    - Cuestionaro de Cuestionario de Evaluación del Estado de Salud ? Índice de discapacidad, cambio desde el inicio a 12 y 24 semanas
    - Puntuación modificada de la actividad de la enfermedad para incluir el recuento de las 28 articulaciones diartrodiales, cambio desde el inicio a 12 y 24 semanas
    - Proporcion de pacientes que hayan conseguido respuesta ACR20 en la semana 12 y 24.
    - Proporcion de pacientes que hayan conseguido respuesta ACR50 y ACR70 en la semana 12 y 24.
    - Proporcion de pacientes que hayan alcanzado DAS28-HCRP <=3.2; proporcion de pacientes que hayan conseguido DAS28-HSCRP < 2.6: a 12 y 24 semanas
    - Proporcion de pacientes que hayan alcanzado DAS28-ESR <=3.2; proporcion de pacientes que hayan conseguido DAS28-ESR < 2.6: a 12 y 24 semanas
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA50
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Belgium
    Canada
    Croatia
    Denmark
    France
    Germany
    Greece
    India
    Israel
    Italy
    Japan
    Korea, Republic of
    Mexico
    Netherlands
    Poland
    Spain
    Switzerland
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    ultima visita ultimo paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months2
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 105
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 420
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state24
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 226
    F.4.2.2In the whole clinical trial 525
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients who complete this study through week 24 will be eligible to participate in a separate extension study (Study I4V-MC-JADY [JADY]) lasting for up to 2 years if enrollment criteria for Study JADY are met or to the posttreatment follow-up period of this study.
    Los pacientes que completen el estudio de 24 semanas participaran en un estudio de extension (Study I4V-MC-JADY [JADY]) que durara un minimo de 2 años-
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-01-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-12-17
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2014-09-02
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA